DDInter1826 DDInter1082
A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Tolazamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolazamide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
Tolazamide {u} (Compound) binds {v} (Gene) KCNJ1
Tolazamide {u} (Compound) upregulates {v} (Gene) TSC22D3
Tolazamide {u} (Compound) is included by {v} (Pharmacologic Class) Sulfonylurea Compounds
Tolazamide {u} (Compound) downregulates {v} (Gene) GDF15
Tolazamide {u} (Compound) causes {v} (Side Effect) Headache
Tolazamide (Compound) resembles Tolbutamide (Compound)
Tolazamide (Compound) treats type 2 diabetes mellitus (Disease)
Tolazamide (Compound) binds KCNJ1 (Gene)
Tolazamide (Compound) upregulates TSC22D3 (Gene)
Tolazamide (Compound) is included by Sulfonylurea Compounds (Pharmacologic Class)
Tolazamide (Compound) downregulates GDF15 (Gene)
Tolazamide (Compound) causes Headache (Side Effect)